Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Sees Strong Trading Volume – Should You Buy?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) saw strong trading volume on Thursday. Approximately 166,025 shares were traded during trading, a decline of 13% from the previous session’s volume of 190,495 shares. The stock last traded at $29.49 and had previously closed at $30.00.

Analysts Set New Price Targets

Several research analysts recently issued reports on LKFT shares. TD Cowen began coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Friday, August 21st. They set a “buy” rating for the company. Royal Bank Of Canada raised shares of Lakefront Biotherapeutics American Depositary Shares from a “sector perform” rating to an “outperform” rating and boosted their price target for the stock from $26.00 to $45.00 in a report on Wednesday, September 23rd. Weiss Ratings upgraded Lakefront Biotherapeutics American Depositary Shares from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, October 2nd. UBS Group upgraded shares of Lakefront Biotherapeutics American Depositary Shares to a “buy” rating in a report on Wednesday, September 23rd. Finally, Morgan Stanley lowered their price target on shares of Lakefront Biotherapeutics American Depositary Shares from $30.00 to $26.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $37.00.

Lakefront Biotherapeutics American Depositary Shares Stock Performance

The company has a market capitalization of $1.92 billion, a PE ratio of -20.67 and a beta of 0.24. The stock’s 50-day simple moving average is $28.42 and its 200 day simple moving average is $28.66.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last released its quarterly earnings data on Monday, August 10th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $1.00. The business had revenue of $15.47 million for the quarter, compared to analyst estimates of $7.29 million. On average, analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -1.27 earnings per share for the current year.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

A number of large investors have recently bought and sold shares of LKFT. ABC Arbitrage SA acquired a new position in Lakefront Biotherapeutics American Depositary Shares during the 1st quarter worth approximately $382,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the first quarter valued at about $248,000. QRG Capital Management Inc. grew its position in Lakefront Biotherapeutics American Depositary Shares by 21.9% during the first quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company’s stock worth $591,000 after buying an additional 3,535 shares during the period. Finally, Madison Avenue Partners LP lifted its position in shares of Lakefront Biotherapeutics American Depositary Shares by 0.8% during the 4th quarter. Madison Avenue Partners LP now owns 2,213,169 shares of the biotechnology company’s stock valued at $72,371,000 after acquiring an additional 17,394 shares during the period. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.